Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 20;12(1):36.
doi: 10.3390/cancers12010036.

Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis

Antonio Facciorusso  1 , Mohamed A Abd El Aziz  2 , Rodolfo Sacco  1
Affiliations
Review

Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis

Antonio Facciorusso et al. Cancers (Basel). .

Abstract

Regorafenib showed promising results as a second-line agent after sorafenib failure in hepatocellular carcinoma patients. The aim of this meta-analysis was to evaluate the efficacy and safety of regorafenib in hepatocarcinoma patients. A computerized bibliographic search was performed on the main databases. The primary outcome was overall survival. Secondary outcomes were progression-free survival, tumor response, and the adverse events rate. Outcomes were pooled through a random-effects model and summary estimates were expressed in terms of median and 95% confidence interval or rates, as appropriate. One randomized-controlled trial and seven non-randomized studies with 809 patients were included. The great majority of recruited patients were in Child-Pugh A and ECOG 0 stage. Median overall survival was 11.08 months (9.46-12.71) and sensitivity analyses confirmed this finding, with a median survival ranging from 10.2 to 13.8 months. Duration of regorafenib therapy was 3.58 months, whereas median progression-free survival was 3.24 months (2.68-3.86). The pooled objective response rate was 10.1% (7.8%-12.5%) while the disease control rate was 65.5% (61.3%-69.7%) with no evidence of heterogeneity (I2 = 0%; Diarrhea, fatigue, and hand-foot skin reaction were the most frequent adverse events. The current meta-analysis shows that regorafenib represents a valuable and relatively safe therapeutic option in intermediate/advanced hepatocellular carcinomapatients who progress on sorafenib.

Keywords: Sorafenib; advanced; cirrhosis; hepatocarcinoma; liver cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow-chart.
Figure 2
Figure 2
Overall survival.
Figure 3
Figure 3
Progression-free survival.
Figure 4
Figure 4
Tumor response. (A) Objective response rate; (B) Disease control rate.
See this image and copyright information in PMC

References

    1. El-Serag H.B. Hepatocellular carcinoma. New Engl. J. Med. 2011;365:1118–1127. doi: 10.1056/NEJMra1001683. - DOI - PubMed
    1. Galle P.R., Forner A., Llovet J.M., Mazzaferro V., Piscaglia F., Raoul J.L., Schirmacher P., Vilgrain V. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019. - DOI - PubMed
    1. Heimbach J.K., Kulik L.M., Finn R.S., Sirlin C.B., Abecassis M.M., Roberts L.R., Zhu A.X., Murad M.H., Marrero J.A. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380. doi: 10.1002/hep.29086. - DOI - PubMed
    1. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., De Oliveira A.C., Santoro A., Raoul J.L., Forner A., et al. Sorafenib in advanced hepatocellular carcinoma. New Engl. J. Med. 2008;359:378–390. doi: 10.1056/NEJMoa0708857. - DOI - PubMed
    1. Wilhelm S.M., Dumas J., Adnane L., Lynch M., Carter C.A., Schütz G., Thierauch K.H., Zopf D. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer. 2011;129:245–255. doi: 10.1002/ijc.25864. - DOI - PubMed

LinkOut - more resources